CAS 128253-31-6 BAY-X-1005 - Analytical Products / Alfa Chemistry

CAT	AP128253316
CAS	128253-31-6
Structure
MDL Number	MFCD00870329
Molecular Weight	361.43
InChI Key	ZEYYDOLCHFETHQ-JOCHJYFZSA-N

Description	≥98% (HPLC)
Solubility	DMSO: 5 mg/mL (clear solution)
Assay	≥98% (HPLC)
Color	white to beige
Form	powder
Size	5MG, 25MG
Storage Conditions	2-8°C

1

Antiedematous Effects of Combination Therapies With the Leukotriene Synthesis Inhibitor BAY X 1005 in the Archidonic Acid-Induced Mouse Ear Inflammation Test

E R Burchardt, R Müller-Peddinghaus

Prostaglandins Leukot Essent Fatty Acids. 1997 Apr;56(4):301-6.

PMID: 9150376

1

BAY X 1005 Attenuates Atherosclerosis in apoE/LDLR - Double Knockout Mice

J Jawień, M Gajda, R Olszanecki, R Korbut

J Physiol Pharmacol. 2007 Sep;58(3):583-8.

PMID: 17928652

1

Favorable Combination Effects of the Leukotriene Synthesis Inhibitor BAY X 1005 and Dexamethasone on Edema Formation in the Arachidonic Acid-Induced Mouse Ear Inflammation Test

E R Burchardt, R Müller-Peddinghaus

Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):5-11.

PMID: 10319912

1

Mode of Action of the New Selective Leukotriene Synthesis Inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl Acetic Acid) and Structurally Related Compounds

A Hatzelmann, R Fruchtmann, K H Mohrs, S Raddatz, R Müller-Peddinghaus

Biochem Pharmacol. 1993 Jan 7;45(1):101-11.

PMID: 8381000

1

Pharmacology of the 5-lipoxygenase Inhibitors BAY Y 1015 and BAY X 1005 in the Horse

F M Cunningham, M Andrews, M F Landoni, P Lees

J Vet Pharmacol Ther. 1997 Aug;20(4):296-307.

PMID: 9280370

* Products or Services Interested: BAY-X-1005 (128253-31-6)
* Your question
* Name
* Email
Verification Code